Literature DB >> 23896583

Fourth International Conference: Modern Vaccines/Adjuvants Formulation--Impact on Future Development: May 15-17 2013, CHUV, Lausanne, Switzerland.

Emmanuel Tupin1.   

Abstract

On the 15-17th of May 2013, about 120 scientists, postdoctoral fellows and professors representing renowned academic institutes and senior scientists and executives from small biotechs, contract research organizations (CROs) and Big Pharma companies, gathered at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland for the 4th international conference on Modern Vaccines and Adjuvants Formulation. Despite this relative small number, the speakers and attendees covered together a very broad field of expertise. Indeed, experts in microbiology, immunology, biochemistry, formulation, virus and nanoparticle characterization, vaccine production, quality control as well as regulatory professionals attended the conference and were able to present their works and discuss new developments within the field of vaccine and adjuvant development, characterization and approval process. This broad diversity was a highpoint of the conference and allowed for a stimulating environment and underlined the complexity of the challenges that the field currently faces in order to develop better or completely new vaccines and adjuvants.

Keywords:  Immunostimulatory complexe (ISCOM); Nanoemulsion (nanoE); Nanoparticle (NP); adjuvant; vaccine

Mesh:

Substances:

Year:  2013        PMID: 23896583      PMCID: PMC3906370          DOI: 10.4161/hv.25934

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  19 in total

Review 1.  Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant.

Authors:  Anna U Bielinska; Michele Gerber; Luz P Blanco; Paul E Makidon; Katarzyna W Janczak; Michael Beer; Benjamin Swanson; James R Baker
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

2.  Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation.

Authors:  Sachiko Hirosue; Iraklis C Kourtis; André J van der Vlies; Jeffrey A Hubbell; Melody A Swartz
Journal:  Vaccine       Date:  2010-10-08       Impact factor: 3.641

3.  PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration.

Authors:  Armando Stano; André J van der Vlies; Mikael M Martino; Melody A Swartz; Jeffrey A Hubbell; Eleonora Simeoni
Journal:  Vaccine       Date:  2010-11-19       Impact factor: 3.641

4.  Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.

Authors:  Rebecca J Cox; Gabriel Pedersen; Abdullah S Madhun; Signe Svindland; Marianne Sævik; Lucy Breakwell; Katja Hoschler; Marieke Willemsen; Laura Campitelli; Jane Kristin Nøstbakken; Gerrit Jan Weverling; Jaco Klap; Kenneth C McCullough; Maria Zambon; Ronald Kompier; Haakon Sjursen
Journal:  Vaccine       Date:  2011-08-22       Impact factor: 3.641

Review 5.  ISCOMs and ISCOMATRIX.

Authors:  Hong-Xiang Sun; Yong Xie; Yi-Ping Ye
Journal:  Vaccine       Date:  2009-05-28       Impact factor: 3.641

6.  Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion.

Authors:  Andrzej Myc; Jolanta F Kukowska-Latallo; Anna U Bielinska; Peter Cao; Piotr P Myc; Katarzyna Janczak; Tracy R Sturm; Michael S Grabinski; Jeffrey J Landers; Katherine S Young; Jennifer Chang; Tarek Hamouda; Michal A Olszewski; James R Baker
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

7.  Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.

Authors:  Anna U Bielinska; Katarzyna W Janczak; Jeffrey J Landers; Paul Makidon; Laurie E Sower; Johnny W Peterson; James R Baker
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

8.  Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates.

Authors:  Anna U Bielinska; Katarzyna W Janczak; Jeffrey J Landers; David M Markovitz; David C Montefiori; James R Baker
Journal:  AIDS Res Hum Retroviruses       Date:  2008-02       Impact factor: 2.205

9.  A novel, killed-virus nasal vaccinia virus vaccine.

Authors:  Anna U Bielinska; Alexander A Chepurnov; Jeffrey J Landers; Katarzyna W Janczak; Tatiana S Chepurnova; Gary D Luker; James R Baker
Journal:  Clin Vaccine Immunol       Date:  2007-12-05

10.  Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine.

Authors:  Paul E Makidon; Anna U Bielinska; Shraddha S Nigavekar; Katarzyna W Janczak; Jessica Knowlton; Alison J Scott; Nicholas Mank; Zhengyi Cao; Sivaprakash Rathinavelu; Michael R Beer; J Erby Wilkinson; Luz P Blanco; Jeffrey J Landers; James R Baker
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.